Renal: Bladder Cancer: Free MSRA Podcast

✅ MSRA Deep Dive: Bladder Cancer – High-Yield RevisionIn this in-depth podcast episode, we break down bladder cancer into a clear, high-yield structure tailored for MSRA exam revision. Based on detailed, structured UK notes and NICE guidelines, we cover all key learning areas — from red flag symptoms like painless hematuria to staging, management, and complications. Whether you're preparing for your MSRA or looking to master urological oncology concepts efficiently, this is your concise yet comprehensive audio companion.🧠 Key Learning Points📌 Definition & TypesBladder cancer is the abnormal growth of cells in the bladder lining, classified as:• Non-muscle invasive vs. muscle-invasive• Most common: Transitional cell carcinoma (TCC)• Others: Squamous cell carcinoma (linked to chronic irritation) and adenocarcinoma📌 Risk Factors• Tobacco smoking – strongest modifiable risk• Occupational exposures – dyes, rubber, textiles• Age >65 years, male sex• Chronic cystitis, bladder stones• Pelvic radiotherapy, cyclophosphamide• Parasitic infection (e.g., Schistosoma haematobium)• HPV-16, Lynch syndrome, family history📌 Symptoms & Red Flags• Painless visible hematuria – most common first symptom• Microscopic hematuria in >60s also warrants investigation• Irritative voiding symptoms: frequency, urgency, dysuria• Pelvic/perineal pain in later stages• Advanced signs: ureteric obstruction, bone pain, weight loss, fatigue, jaundice📌 Differential Diagnosis• UTI• Nephrolithiasis (kidney stones)• Hemorrhagic cystitis• Renal cancer, trauma, BPH📌 Investigations• Urinalysis, FBC, renal profile• Cystoscopy with biopsy – gold standard• Urine cytology – useful in CIS• CT urogram for upper tract imaging• Staging: CT chest/abdomen/pelvis, bone scan, LFTs, ALP• NICE referral criteria:≥45 with visible hematuria≥60 with non-visible hematuria + dysuria or raised WBC📌 Staging (TNM)• Tis/Ta/T1 – non-muscle invasive• T2+ – muscle-invasive• N1-3 – pelvic lymph node spread• M1 – distant metastasis📌 Management🔹 Non-muscle invasive (Tis, Ta, T1):• TURBT (transurethral resection)• Intravesical chemo (e.g., mitomycin C)• BCG immunotherapy for high-risk cases🔹 Muscle-invasive (T2+):• Neoadjuvant chemotherapy (cisplatin)• Radical cystectomy with pelvic lymph node dissection• Urinary diversion (e.g., ileal conduit or neobladder)• Adjuvant chemo or radiotherapy in selected cases🔹 Metastatic disease:• Cisplatin-based chemo• If unfit: Carboplatin regimens, single agents• Immunotherapy:Avelumab for maintenanceNivolumab post-op in high-risk cases📌 Palliative Care• Radiotherapy for bleeding or pain• Stenting/nephrostomy for ureteral obstruction• Embolisation or nerve blocks for pain relief📌 Prognosis• Tis/Ta/T1: 5-year survival 80–90%• T2+: drops to 30–60%• M1 (metastatic): ~10–15%• High recurrence risk, requiring long-term surveillance• Follow-up includes regular cystoscopy and upper tract imaging📌 Complications• Recurrence, UTIs, urinary retention, hydronephrosis• ED and urinary incontinence post-surgery• Bowel obstruction, infection, upper tract tumors🔗 Bladder Cancer Resources for the MSRA📄 Revision Notes: https://www.passthemsra.com/topic/bladder-cancer-revision-notes-2/💬 Flashcards: https://www.passthemsra.com/topic/bladder-cancer-flashcards-2/🧠 Accordion Q&A: https://www.passthemsra.com/topic/bladder-cancer-accordion-qa-notes-2/📝 Rapid Quiz: https://www.passthemsra.com/topic/bladder-cancer-rapid-quiz-2/📚 Course Hub: https://www.passthemsra.com/courses/renal-for-the-msra/🏷️ Hashtags#MSRA #MSRARevisionNotes #MSRATextbook #MSRAFlashcards #MSRAQuiz #MSRAQuestionBank #MSRAQANotes #MSRAAccordions #Renal #BladderCancer #UrologyMSRA #PainlessHematuria #UKGuidelines #PassTheMSRA #FreeMSRA